Regeneron Pharmaceuticals Inc (REGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... [Yahoo! Finance]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Yahoo! Finance
Dupixent Global Net Sales: $4.9 billion in Q4 2025, $17.8 billion for the full year 2025. Libtayo Global Net Sales: $425 million in Q4 2025, $1.45 billion for the full year 2025. EYLEA HD US Net Sales: $506 million in Q4 2025, $1.6 billion for the full year 2025. Sanofi Collaboration Revenue: Approximately $1.6 billion in Q4 2025. Bayer Collaboration Revenue: $319 million in Q4 2025. Net Income: $1.2 billion in Q4 2025. Diluted Net Income Per Share: $11.44 in Q4 2025. R&D Expense: $1.3 billion in Q4 2025. SG&A Expense: $691 million in Q4 2025. Free Cash Flow: $4.1 billion in 2025. Cash and Marketable Securities Less Debt: $16.2 billion at the end of Q4 2025. Share Repurchases: $3.4 billion in 2025. Quarterly Dividend: $0.94 per share, equivalent to $3.76 annually. Warning! GuruFocus has detected 8 Warning Signs with REGN. Is REGN fairly valued? Test your thesis with our free DCF calculator. Release Date: January 30, 2026 For the complete transcript of
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating AllergyGlobeNewswire
- Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Guggenheim from $865.00 to $975.00. They now have a "buy" rating on the stock.MarketBeat
- Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=REGN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">WallMarketBeat
- A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Pullback [Yahoo! Finance]Yahoo! Finance
REGN
Earnings
- 1/30/26 - Beat
REGN
Sec Filings
- 2/9/26 - Form 144
- 2/9/26 - Form 144
- 2/6/26 - Form 13F-HR
- REGN's page on the SEC website